The clinical development of tubulin binding vascular disrupting agents

Vascular Disruptive Agents for the Treatment of Cancer

Volumn , Issue , 2010, Pages 183-216

  Zweifel, Martin ^a   Rustin, Gordon ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874707179     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-6609-4_9     Document Type: Chapter

References (118)

1. Akerley, W. L., M. Schabel, et al. (2007). A randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25(18S): 14060.
2. Anderson, H., J. T. Yap, et al. (2003). Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 89(2): 262-7.
3. Anderson, H. L., J. T. Yap, et al. (2003). Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21(15): 2823-30.
4. Aprile, S., E. Del Grosso, et al. (2007). In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes. Drug Metab Dispos 35(12): 2252-61.
5. Badn, W., S. Kalliomaki, et al. (2006). Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma. Clin Cancer Res 12(15): 4714-19.
6. Bai, R., M. C. Edler, et al. (2009). Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol 75(1): 218-26.
7. Bilenker, J. H., K. T. Flaherty, et al. (2005). Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 11(4): 1527-33. Bionomics http://www.bionomics.com.au/page.php?section=129 (accessed March 2009).
8. Blakey, D. C., S. E. Ashton, et al. (2002). ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54(5): 1497-502.
9. Blakey, D. C., F. R. Westwood, et al. (2002). Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8(6): 1974-83.
10. Boehle, A. S., B Sipos, et al. (2001). Combretastatin A-4 prodrug inhibits growth of human nonsmall cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 71(5): 1657-65.
11. Breidahl, T., F. U. Nielsen, et al. (2006). The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone- 4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS. Acta Oncol 45(3): 306-16.
12. Burris, H., S. Freedman, et al. (2008). A phase 1 study of LP-261 in patients with advanced solid malignancies. AACR Meeting Abstracts 2008(1 Annual Meeting): 1421.
13. Chaplin, D. and G. Dougherty (1999). Tumour vasculature as a target for cancer therapy. Br J Cancer 80(Suppl 1): 57-64.
14. Chaplin, D. J., G. R. Pettit, et al. (1996). Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 74(Suppl 27): S86-S88.
15. Chaplin, D. J., G. R. Petit, et al. (1999). Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4-phosphate. Anticancer Res 19: 189-196.
16. Chaplin, D. J., G. R. Pettit, et al. (1999). Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19(1A): 189-95.
17. Collins, J. M. (2003). Functional imaging in phase I studies: decorations or decision making? J Clin Oncol 21(15): 2807-9.
18. Cooney, M. M., T. Radivoyevitch, et al. (2004). Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10(1 Pt 1): 96-100.
19. Cooney, M. M., P. Savvides, et al. (2006). Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I(18S): 5580.
20. Cruz-Monserrate, Z., H. C. Vervoort, et al. (2003). Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin. Mol Pharmacol 63(6): 1273-80.
21. Cunningham, C., L. J. Appleman, et al. (2005). Phase I and pharmacokinetic study of the dolastatin- 15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 11(21): 7825-33. Cytopia http://www.cytopia.com.au/glance.html#pcvprogram (accessed March 2009)
22. Dark, G. G., S. A. Hill, et al. (1997). Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57(10): 1829-34.
23. Davis, P. D., G. J. Dougherty, et al. (2002). ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62(24): 7247-53.
24. Davis, P. D., G. M. Tozer, et al. (2002). Enhancement of vascular targeting by inhibitors of nitric oxide synthase. Int J Radiat Oncol Biol Phys 54(5): 1532-6.
25. de Jonge, M. J., A. van der Gaast, et al. (2005). Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 11(10): 3806-13.
26. DelProposto, Z., P. LoRusso, et al. (2002). MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature. Proc Am Soc Clin Oncol 21: abstract 440.
27. Dowlati, A., K. Robertson, et al. (2002). A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62(June 15): 3408-16.
28. Dziba, J. M., R. Marcinek, et al. (2002). Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 12(12): 1063-70.
29. Ebbinghaus, S., E. Rubin, et al. (2005). A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 11(21): 7807-16.
30. el Zayat, A. A., D. Degen, et al. (1993). In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs. 4(1): 19-25. EpiCept http://www.epicept.com/Product-Pipeline/Cancer/EPC2407/(accessed March 2009).
31. Foley, K., C. Borella, et al. (2008). Vascular disrupting agent STA-9584 selectively targets microvasculature at both the center and periphery of tumors. AACR Meeting Abstracts 2008(1 Annual Meeting): 1444.
32. Gadgeel, S. M., P. M. LoRusso, et al. (2002). A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. Proc Am Soc Clin Oncol 21: abstract 438.
33. Galbraith, S. M., Chaplin, D. J. et al. (2001). Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21(1A): 93-102.
34. Galbraith, S. M., R. J. Maxwell, et al. (2003). Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21(15): 2831-42.
35. Gardner, E., E. Springman, et al. (2007). Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. AACR Meeting Abstracts 2007(1 Annual Meeting): 1423.
36. Gaukroger, K., J. A. Hadfield, et al. (2001). Novel syntheses of cis and trans isomers of combretastatin A-4. J Org Chem 66(24): 8135-8.
37. Gaukroger, K., J. A. Hadfield, et al. (2003). Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit? Org Biomol Chem 1(17): 3033-7.
38. Gaya, A. M. and G. J. Rustin (2005). Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 17(4): 277-90. Genzyme http://www.genzymeoncology.com/onc/research/onc-p-research.asp (accessed March 2009).
39. Gourdeau, H., L. Leblond, et al. (2004). Antivascular and antitumor evaluation of 2-amino-4-(3- bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents. Mol Cancer Ther 3(11): 1375-84.
40. Greystoke, A., S. Blagden, et al. (2006). A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann Oncol 17(8): 1313-9.
41. Griggs, J., J. C. Metcalfe, et al. (2001). Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2(2): 82-7.
42. Grosios, K., S. E. Holwell, et al. (1999). In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81 (8): 1318-27.
43. Grosios, K., P. M. Loadman, et al. (2000). Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20(1A): 229-33.
44. Guatteo, E., L. Bianchi, et al. (1996). A novel K + channel blocker isolated from hiccup nut toxin. Neuroreport 7(15-17): 2575-9.
45. Hanahan, D., G. Bergers, et al. (2000). Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105(8): 1045-7.
46. Harrigan, G. G., H. Luesch, et al. (1998). Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J Nat Prod 61(9): 1075-7.
47. Hashiguchi, N., T. Kubota, et al. (2004). TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply. Anticancer Res 24(4): 2201-8.
48. Hill, S. A., D. J. Chaplin, et al. (2002). Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer 102(1): 70-4.
49. Hill, S. A., G. M. Tozer, et al. (2002). Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res. 22(3): 1453-58.
50. Hoffman, M. A., J. A. Blessing, et al. (2003). A phase II trial of dolastatin-10 in recurrent platinumsensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 89 (1): 95-8.
51. Horgen, F. D., E. B Kazmierski, et al. (2002). Malevamide D: isolation and structure determination of an isodolastatin H analogue from the marine cyanobacterium Symploca hydnoides. J Nat Prod 65(4): 487-91.
52. Hori, K. and S. Saito (2003). Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 89(7): 1334-44.
53. Hori, K., S. Saito, et al. (1999). Antitumor effects due to irreversle stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90(9): 1026-38.
54. Horti, J., E. Juhasz, et al. (2008). Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. Cancer Chemother Pharmacol 62(1): 173-80.
55. Hua, J., Y. Sheng, et al. (2003). Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 23(2B): 1433-40.
56. Jordan, M. A., D. Walker, et al. (1998). Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry 37(50): 17571-8.
57. Kasibhatla, S., H. Gourdeau, et al. (2004). Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Mol Cancer Ther 3(11): 1365-74.
58. Kerbrat, P., V. Dieras, et al. (2003). Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. Eur J Cancer 39(3): 317-20.
59. Kindler, H. L., P. K. Tothy, et al. (2005). Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs 23(5): 489-93.
60. Kobayashi, M., T. Natsume, et al. (1997). Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88(3): 316-27.
61. Kremmidiotis, G., T. Lavranos, et al. (2008). BNC105P is a vascular disruption agent that exhibits dual mode of action in a number of cancer indications and works additively in combination with bevacizumab. AACR Meeting Abstracts 2008(1 Annual Meeting): 1445.
62. Landuyt, W., O. Verdoes, et al. (2000). Vascular targeting of solid tumours: a major inverse volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 36(14): 1833-43.
63. Lejeune P, H. T., Vrignaud P et al (2002). In vivo antitumour activity and tumor necrosis induced by AVE8062A, a tumour vascular targeting agent.Proc AACR 43(156): Abstr 781.
64. Li, L., A. Rojiani, et al. (1998). Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42(4): 899-903.
65. Lickliter, J., A. Francesconi, et al. (2008). Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer. J Clin Oncol 26(May 20 suppl): abstr 3504.
66. Lin, C. M., S. B Singh, et al. (1988). Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 34(2): 200-8.
67. Lin, C. M., H. H. Ho, et al. (1989). Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 28(17): 6984-91.
68. Lippert, J. W., 3rd (2007). Vascular disrupting agents. Bioorg Med Chem 15(2): 605-15.
69. LoRusso, P. M., S. M. Gadgeel, et al. (2008). Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 26(2): 159-67.
70. Madden, T., H. T. Tran, et al. (2000). Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 6(4): 1293-301.
71. Malcontenti-Wilson, C., I. D. Phillips, et al. (2005). Selective targeting of tumor vasculature by the novel synthetic molecule CYT997 and its efficacy in preclinical cancer models. AACR Meeting Abstracts 2005(1): 808.
72. Mandeville, H. C., V. Goh, et al. (2008). Volumetric perfusion CT assessment of concurrent combretastatin-A4-phosphate (CA4P) and radiotherapy (RT) in non-small cell lung cancer. J Clin Oncol 26(May 20 suppl): abstr 14517
73. Margolin, K., J. Longmate, et al. (2001). Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs 19(4): 335-40.
74. Marks, R. S., D. L. Graham, et al. (2003). A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. Am J Clin Oncol 26(4): 336-7.
75. McCreedy, B K., T Locke, KW (2004). The novel vascular disrupting agent, MN-029, shows potent and selective anti-tumour activity in preclinical animal models. Proc 2nd International Conference On Vascular Targeting, Miami, Florida: Abstract 23
76. McDermott, D. F., E. Hersh, et al. (2005). ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma:phase II experience. ASCO Annual Meeting Proceedings 23(16S, Part I of II (June 1 Supplement)): 7556. Medicinova http://www.medicinova.com/html/research-cancer.html (accessed March 2009)
77. Meyer, T., A. M. Gaya, et al. (2009). A phase I trial of radioimmunotherapy with 131I-A5B7 anti- CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res 15(13): 4484-92.
78. Mita, A. C., L. A. Hammond, et al. (2006). Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res 12(17): 5207-15.
79. Mita, A. C., L. K. Yee, et al. (2008). Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. J Clin Oncol 26(May 20 suppl): abstr 3525
80. Mross, K., W. E. Berdel, et al. (1998). Clinical and pharmacologic phase I study of Cemadotin- HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society. Ann Oncol 9(12): 1323-30.
81. Nathan, P., I. Judson, et al. (2008). A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 26 (May 20 suppl): 3550.
82. Ng, Q. S., V. Goh, et al. (2007). Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 67(5): 1375-80.
83. Nicholson, B., G. K. Lloyd, et al. (2006). NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 17(1): 25-31.
84. Oliver, R., C. Wheeler, et al. (2004). Evaluation of the role of body-surface-area dose adjustment of ZD6126, a novel vascular-targeting agent. ASCO Annual Meeting Proceedings 22 (14S): 3065 Oxigene (2008). Investigators brochure CA4P (Edition 15).
85. Patel, S., M. L. Keohan, et al. (2006). Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 107(12): 2881-7.
86. Patterson, D. M., N. Charnley, et al. (2008). Phase I evaluation of vascular disrupting agent OXi4503. J Clin Oncol 26(May 20 suppl): abstract 3551
87. Pedley, R. B., S. A. Hill, et al. (2001). Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 61(12): 4716-22.
88. Perez, E. A., D. W. Hillman, et al. (2005). Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs 23(3): 257-61.
89. Pettit, G. R., C. Temple, Jr., et al. (1995). Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10: 299-309.
90. Pitot, H. C., E. A. McElroy, Jr., et al. (1999). Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5(3): 525-31.
91. Prise, V. E., D. J. Honess, et al. (2002). The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21(4): 717-26.
92. Radema, S. A., L. V. Beerepoot, et al. (2002). Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage. Proc Am Soc Clin Oncol 21: abstract 439
93. Ray, A., T. Okouneva, et al. (2007). Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res 67(8): 3767-76.
94. Ricart, A. D., M. Cooney, et al. (2006). A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 24(18S (June 20 Supplement)): 3096
95. Riely, G. J., S. Gadgeel, et al. (2007). A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 55(2): 181-5.
96. Rustin, G. J., S. M. Galbraith, et al. (2003). Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21(15): 2815-22.
97. Rustin, G. J., P. D. Nathan, et al. (2005). A Phase Ib Trial Of Combretastatin A4 Phosphate (CA4P) In Combination With Carboplatin Or Paclitaxel Chemotherapy In Patients With Advanced Cancer. Proc ASCO 23: Abstract 3103: 217s
98. Rustin, G., G. Jayson, et al. (2008). Fosbretabulin combretastatin A-4 phosphate [CA4P] carboplatin and paclitaxel is active in patients with platinum resistant ovarian cancer. IGCS 2008, 12th Biennial Meeting, International Gynecologic Cancer Society, Bangkok, Thailand.
99. Saad, E. D., E. H. Kraut, et al. (2002). Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol 25(5): 451-3.
100. Schoffski, P., B Thate, et al. (2004). Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 15(4): 671-9.
101. Scurr, M., I. Judson, et al. (2004). Assessment of metabolism, excretion and pharmacokinetics of a single dose of [14C]-ZD6126 in patients with solid malignant tumors. ASCO Annual Meeting Proceedings 22(14S): 3083
102. Segreti, J. A., J. S. Polakowski, et al. (2004). Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 54(3): 273-81.
103. Shaked, Y., A. Ciarrocchi, et al. (2006). Impact of circulating endothelial progenitor cells on the growth of viable tumor rim after treatment with a vascular disrupting agent. AACR Meeting Abstracts 2006(1): 1343.
104. Shaked, Y., A. Ciarrocchi, et al. (2006). Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313(5794): 1785-87.
105. Shaked, Y., E. Henke, et al. (2008). Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14(3): 263-73.
106. Siemann, D. and W. Shi (2005). Dual agent targeting of the tumor vasculature: combining avastin with CA4P or OXi4503. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
107. Smyth, J., M. E. Boneterre, et al. (2001). Activity of the dolastatin analogue, LU103793, in malignant melanoma. Ann Oncol 12(4): 509-11.
108. Stevenson, J. P., M. Rosen, et al. (2003). Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21(23): 4428-38.
109. Supko, J. G., T. J. Lynch, et al. (2000). A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemother Pharmacol 46(4): 319-28.
110. Therasse, P., S. G. Arbuck, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-16.
111. Thorpe, P. E., D. J. Chaplin, et al. (2003). The first international conference on vascular targeting: meeting overview. Cancer Res 63(5): 1144-7.
112. Tolcher, A. W., L. Forero, P. Celio, L. A. Hammond, A. Patnaik, M. Hill, C. Verat-Follet, M. Haacke, M. Besenval, E. K. Rowinsky (2003).Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days. Proc Am Soc Clin Oncol 22: Abstract 834.
113. Villalona-Calero, M. A., S. D. Baker, et al. (1998). Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. J Clin Oncol 16(8): 2770-9.
114. von Mehren, M., S. P. Balcerzak, et al. (2004). Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas. Sarcoma 8(4): 107-11.
115. Vrignaud, P. (2004). In vivo synergy between cytotoxic agents and AVE8062A, a tumour vascular targeting agent. Proc 2nd International Conference On Vascular Targeting, Miami, Florida: Abstract 8.
116. Woods, J. A., J. A. Hadfield, et al. (1995). The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71: 705-11.
117. Yamamoto, N., M. Andoh, et al. (2008). Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci Dec 8 [Epub ahead of print]
118. Yeung, S. C., M. She, et al. (2007). Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 92(8): 2902-9.